LFMD earnings analysis
What we found in LFMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
LifeMD reported Q1 2026 revenue of $50.2 million, a slight decline of 1% from $50.9 million in Q1 2025, but exceeding estimates by 2.9%. The firm reported a wider EPS loss of $0.20 compared to the expected loss of $0.13, contributing to a negative sentiment around earnings despite improvements in gross margins and subscriber growth.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 Revenue Exceeds Estimates
- Actual revenue was $50.2 million, surpassing estimates of $48.8 million by 2.9%.
- Improved Gross Margins
- Gross profit margin increased to 88.2% in Q1 2026 from 84.0% in Q1 2025.
- Significant Subscriber Growth
- LifeMD served over 365,000 active patient subscribers as of March 31, 2026.
- Cash Reserves of $34.5 Million
- Cash position remained robust, providing a buffer for operational needs.
- Operating Expenses Increased
- Total expenses surged by 21% to approximately $53.2 million, driven by higher marketing costs.
- Cash Flow From Operations
- Net cash provided by operating activities was approximately $445K, down from $3.1 million in the prior year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Widening EPS Loss
- Q1 2026 EPS was a loss of $0.20, compared to a loss of $0.06 in Q1 2025.
- Increased Operating Expenses
- Operating expenses rose 21% year-over-year, outpacing revenue growth.
- Liquidity Concerns
- Working capital decreased by $8.15 million to $2.1 million as cash decreased by $2.3 million.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.2
- Gross margin
- 88.2%
What they said about what is next.
Management reaffirmed full-year 2026 revenue guidance of $220M to $230M.
The filing reads worse than the one before it.
What came before.
- 10-K · March 10, 2026
- LifeMD’s 2025 10-K emphasizes a vertically integrated, subscription-driven telehealth and pharmacy platform with scale initiatives (wholly-owned pharmacy, AI-enabled systems) and continued patient growth. The filing…
- 10-Q · November 17, 2025
- LifeMD reported Q3 revenue of $60,172,470, up $6,900,176 (+12.95%) versus Q3 2024 but down modestly versus Q2 2025. Gross margin compressed to 87.7% (from 90.6% a year ago) while operating loss narrowed to $(1,969,214)…
- 10-Q · August 5, 2025
- LifeMD reported Q2 revenue of $62,218,185 (up from $50,661,845 in Q2 2024) and a diluted loss per share of $(0.06). Gross profit improved to $54,787,281 and operating loss narrowed to $(906,772). The company generated…
- 10-Q · May 6, 2025
- LifeMD reported strong top-line growth for the quarter: total revenue of $65,697,756 (up from $44,144,264 a year ago) and gross profit of $57,054,040. Operating income flipped to positive $2,542,924 (vs. an operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LFMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever